Evidence map›Paper›PMID 41159479›Full record

Trial reportEuropean journal of heart failure2025

Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The HELIOS-B trial.

Awais Sheikh, Zi Michael Miao, Brian Claggett, Pablo Garcia-Pavia, Francesco Cappelli, Emre Aldinc, Julian Gillmore, Scott D Solomon, Marianna Fontana

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Awais SheikhNational Amyloidosis Centre, University College London, London, UK.
Zi Michael MiaoCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Brian ClaggettCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Pablo Garcia-PaviaDepartment of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV, and Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Francesco CappelliTuscan Regional Amyloid Center, Careggi University Hospital, Florence, Italy.
Emre AldincAlnylam Pharmaceuticals, Cambridge, MA, USA.
Julian GillmoreNational Amyloidosis Centre, University College London, London, UK.
Scott D SolomonCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Marianna FontanaNational Amyloidosis Centre, University College London, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTransthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive condition primarily affecting older adults, who are at increased risk of morbidity and mortality. In HELIOS-B, vutrisiran reduced all-cause mortality and recurrent cardiovascular events versus placebo in patients with ATTR-CM. This prespecified analysis evaluated efficacy and safety outcomes by age category (<75, 75 to <80, and ≥80 years) and across age as a continuous measure. METHODS AND

resultsHELIOS-B randomized patients with ATTR-CM in a 1:1 ratio to vutrisiran 25 mg or placebo every 12 weeks for up to 36 months. Eligible patients were aged 18-85 years. We assessed the primary composite of all-cause mortality and recurrent cardiovascular events, changes in 6-min walk test (6MWT) and Kansas City Cardiomyopathy Questionnaire overall summary score (KCCQ-OSS), and safety outcomes across age groups. Among 654 patients (aged 45-85 years; mean 75.3 ± 6.7), 257 (39.3%) were <75, 201 (30.7%) 75 to <80, and 196 (30.0%) ≥80 years. Vutrisiran reduced the risk of the primary composite outcome in all age categories (p

conclusionsVutrisiran reduced all-cause mortality and cardiovascular events and maintained function and quality of life in patients with ATTR-CM across the age spectrum, including those ≥80 years.

Indexed as

Amyloid Neuropathies, FamilialCardiomyopathiesAdolescentAdultAgedAged, 80 and overAge FactorsDouble-Blind MethodFemaleHumansMaleMiddle AgedQuality of LifeTreatment OutcomeYoung AdultCardiovascular outcomesFunctional capacityHELIOS‐BMortalityTransthyretin cardiomyopathyVutrisiran

Identifiers

PMID41159479
PMCPMC12803538

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.